Veracyte (VCYT) Stock Forecast & Price Target

Veracyte is supported by a durable core of market-leading genomic classifiers, with Afirma and Decipher backed by strong reimbursement, guideline inclusion, and deep real-world evidence that create a wide competitive moat and sustain double-digit growth. The company has also demonstrated unusually strong operating leverage, generating $517.2 million of revenue in FY2025, 27.56% adjusted EBITDA margin, $136.3 million of operating cash flow, and $439.1 million of cash with zero debt as of March 31, 2026. Its outlook is further strengthened by a self-funded pipeline of high-value launches and acquisitions, including TrueMRD, Prosigna, and Convergent, which expand the addressable market across urology, breast, and bladder cancer while adding longer-term growth optionality.

Veracyte is viewed negatively because its growth depends heavily on a small number of flagship tests while adoption remains uneven, with Afirma only ~38% penetrated in a ~180,000-patient U.S. addressable market and the thyroid market growing only in the low-single digits. Pricing and volume are vulnerable as Medicare rose to ~20% of FY2025 revenue and UnitedHealthcare to ~14%, while lab benefit managers, prior authorization, and rate cuts create persistent reimbursement pressure and margin risk. Competitive intensity is also rising across urology, breast, and MRD diagnostics, making it harder for Decipher, Prosigna, and newer pipeline efforts to offset weak sales, adverse policy changes, or underwhelming execution.